S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update

(1) Department of Dermatology, University of Lübeck, Lübeck, Germany (2) Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany (3) Department of Dermatology, University Hospital Erlangen, Erlangen, Germany (4) Department of Dermatology and Venereology, University Hospital Munich (LMU), Munich, Germany (5) Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany (6) Department of Dermatology, Venereology, and Allergology, University Hospital Würzburg, Würzburg, Germany (7) Helios University Hospital Wuppertal, Department of Dermatology, Allergology and Dermatosurgery, Wuppertal, Germany (8) Department of Dermatology and Venereology, University of Cologne, Cologne, Germany (9) Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany (10) Dermatologist in Private Practice, Fulda, Germany (11) Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Dermatology, Venereology und Allergy, Division of Evidence based Medicine (dEBM), Berlin, Germany (12) Gilead Sciences GmbH, Martinsried, Germany (13) Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institut für Klinische Pharmakologie und Toxikologie, Berlin, Germany (14) Department of Dermatology and Allergology, University Hospital Ulm, Ulm, Germany (15) Pediatric Immunology and Rheumatology, University Hospital and Outpatient Clinic for Pediatrics, Leipzig, Germany (16) Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Dermatology, Venereology und Allergy, Allergy Center, Berlin, Germany